DR

Dr Reddy's Laboratories LtdNSE DRREDDY Stock Report

Last reporting period 31 Mar, 2024

Updated 18 Sep, 2024

Last price

Market cap $B

4.703

Middle

Exchange

XNSE - National Stock Exchange Of India

DRREDDY.NS Stock Analysis

DR

Attractive

Based on Eyestock quantitative analysis, DRREDDY.NS`s fundamental data and valuation indicate an investment grade of Attractive at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

110/100

High score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

24.0 %

Undervalued

Market cap $B

4.703

Dividend yield

0.59 %

Shares outstanding

166.51 B

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. The company is headquartered in Hyderabad, Telangana and currently employs 24,832 full-time employees. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. The company works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.

View Section: Eyestock Rating